Stock ORGO ORGANOGENESIS HOLDINGS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Organogenesis Holdings Inc.

Equities

ORGO

US68621F1021

Market Closed - Nasdaq
Other stock markets
 21:30:01 03/05/2024 BST 		5-day change 1st Jan Change
2.49 USD 0.00% Intraday chart for Organogenesis Holdings Inc. +5.96% -39.12%
05-02 Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis CI
02-29 Transcript : Organogenesis Holdings Inc., Q4 2023 Earnings Call, Feb 29, 2024

Evolution of the average Target Price on Organogenesis Holdings Inc.

Price target over the last 5 years

History of analyst recommendation changes

f50725b408bb06126699ed42f30.Ogzfud_LeDoHWcg4zMr3OknGx-Gemp-CONAVCHW7Gg4.bnmUwIieMw5NGK5X-_3BUz7-8YDJ0f6wVYJBTRLwX2N8aJjYsq0CCTYfpw~f44ef98833f0b16002e912fdfa955806

Analyst Recommendations on Organogenesis Holdings Inc.

BTIG Raises Price Target on Organogenesis Holdings to $6 From $4, Keeps Buy Rating MT
Morgan Stanley Adjusts Price Target on Organogenesis to $3.50 From $3, Maintains Equalweight Rating MT
Hopes of rate peak, China turnaround lift stocks AN
Morgan Stanley Adjusts Price Target on Organogenesis Holdings to $3 From $5, Maintains Equal-Weight Rating MT
Morgan Stanley Starts Organogenesis Holdings at Equalweight With $5 Price Target MT
BTIG Upgrades Organogenesis to Buy From Neutral, Price Target is $10 MT
BTIG Downgrades Organogenesis Holdings to Neutral From Buy MT
Oppenheimer Downgrades Organogenesis Holdings to Perform From Outperform, Removes $14 Price Target MT
SVB Leerink Adjusts Organogenesis Holdings' Price Target to $20 from $26, Keeps Outperform Rating MT
ORGANOGENESIS : Oppenheimer Adjusts Organogenesis Holdings PT to $28 From $25 on Strong Q1 Beat and Raised Guidance, Maintains Outperform Rating MT
ORGANOGENESIS : Oppenheimer Adjusts Price Target on Organogenesis Holdings to $25 From $21, Keeps Outperform Rating MT
ORGANOGENESIS : SVB Leerink Adjusts Price Target on Organogenesis Holdings to $22 From $19, Maintains Outperform Rating MT
ORGANOGENESIS : Credit Suisse Raises Organogenesis Holdings' PT to $21 from $9, Expects Continued Success of Commercial Execution Strategy; Keeps Outperform Rating MT
ORGANOGENESIS : SVB Leerink Adjusts Organogenesis Holdings' Price Target to $13 From $10, Keeps at Outperform MT
ORGANOGENESIS : Oppenheimer Adjusts Price Target on Organogenesis Holdings to $13 From $9, Maintains Outperform Rating MT
ORGANOGENESIS : Credit Suisse Adjusts Organogenesis Holdings' Price Target to $9 from $8, Keeps Outperform Rating MT
ORGANOGENESIS : SVB Leerink Adjusts Organogenesis Holdings' Price Target to $10 From $9, Keeps at Outperform MT
ORGANOGENESIS : Credit Suisse Adjusts Organogenesis Holdings' Price Target to $8 from $7, Keeps Outperform Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
2.49 USD
Average target price
4.833 USD
Spread / Average Target
+94.11%
High Price Target
6 USD
Spread / Highest target
+140.96%
Low Price Target
3.5 USD
Spread / Lowest Target
+40.56%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Organogenesis Holdings Inc.

BTIG
Morgan Stanley
Oppenheimer
SVB Leerink
Credit Suisse

Ratings for Organogenesis Holdings Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. ORGO Stock
  4. Consensus Organogenesis Holdings Inc.